(Shijiazhuangxun) The Chinese domestic MRNA (messenger ribonucleic acid) coronary vaccine developed by Hebei Shizhen Group was vaccinated on Saturday (May 13) in a community health service center in Shijiazhuang.
Hebei Daily disclosed the above news Saturday.
The MRNA vaccine of the Stone Medicine Group was approved by the National Health and Health Commission of China on March 22. It was included in emergency use. It can be used for people over 18 years of age to strengthen immune vaccination.Strengthen immunity to priority vaccine.It is also the only MRNA vaccine approved by mainland China.
Hebei Daily reports emphasized that the key raw materials and auxiliary materials used in the MRNA vaccine used by the Stone Medicine Group, such as core lipids and mRNA preparation hats and analogs, are all produced by Stone Medicine Group, and other auxiliary materials are domesticized.
Previous stone medicine group, known as China Pharmaceutical Group Co., Ltd., is an investment holding private enterprise mainly engaged in pharmaceutical production and sales.It was listed on the main board of the Hong Kong Stock Exchange in June 1994.
